Patient Registry of Intrathecal Ziconotide Management(PRIZM)
Patient Registry of Intrathecal Ziconotide Management(PRIZM)
The objectives of this study are to evaluate the effectiveness, long-term safety,
 tolerability, satisfaction with treatment, and health-related quality of life (HRQoL)
 associated with Intrathecal PRIALT use for severe chronic pain of varying etiologies.
Inclusion Criteria:

 -  Patient is at least 18 years of age at the time of study entry.

 -  Patient who has severe chronic pain, whom IT therapy is warranted, and who is
 intolerant of, or refractory to other treatments, such as systemic analgesics,
 adjunctive therapies, and/or IT morphine.

 -  Patient is planned to be initiated on IT PRIALT as the sole agent in the pump at a
 participated site.

 -  Patient has not received PRIALT treatment administered continuously via Medtronic
 SynchroMed® II pump within the past 30 days.

 -  Patient has a life expectancy >6 months as determined by the physician.

 -  Patient is able to read, understand, and voluntarily sign the IRB-approved informed
 consent document prior to the performance of any study-specific procedures.

 -  Patient is able to understand and complete required assessments.

 Exclusion Criteria:

 -  Patient has a known hypersensitivity to PRIALT or any of its formulation components.

 -  Patient has a pre-existing history of psychosis.

 -  Patient has infection at the microinjection site, uncontrolled bleeding diathesis, or
 known spinal canal obstruction that impairs circulation of cerebrospinal fluid.

 -  Patient is being initiated with PRIALT in conjunction with other IT agents.

 -  Patients with any other concomitant treatment or medical condition that, in the
 opinion of the clinician, would render IT administration hazardous.